Navigation Links
Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
Date:4/2/2012

HAYWARD, Calif., April 2, 2012 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that its Board of Directors has appointed Kurt Graves to the position of Chairman, President and Chief Executive Officer (CEO), effective immediately.  Mr. Graves has been the Executive Chairman of the Board since August 2010 and Acting CEO since October 2011, bringing Intarcia more than 20 years of leadership and global experience in building and growing top-performing pharmaceutical and biotechnology companies.  The Company today also announced its intention to locate its new corporate headquarters in the Boston, Massachusetts area, while keeping its early development capabilities and state-of-the-art manufacturing site in Hayward, California. 

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

"Intarcia has proven itself an innovative and powerful force capable of creating game-changing medicines for serious diseases.  The Board believes that Intarcia's full potential will be realized under the continued direct leadership and ongoing vision of Kurt Graves," said Director Bryan Roberts, Partner at Venrock.  "Kurt's strategic insights across the business and his passion to bring new medicines to patients has lifted the Company to a whole new level.  We believe his permanent appointment as CEO, combined with the Company's recent announcements, form a strong and promising future for the Company.  In addition, our concurrent plan to locate Intarcia's headquarters in the Boston area reveals our level of commitment to this forward leadership."

Mr. Graves is credited by the Board for seeing major new opportunities early on at Intarcia and for reshaping a bold vision and strategic direction for the Company and its lead candidate for diabetes.
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
6. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
7. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... a paper published this week in Science , researchers ... learned how bats can home in on a target, while ... their midst. The trick lies in their neurons: Bats can ... by distinguishing changes in amplitude the intensity of the ...
... July 28, 2011 Gen-Probe Incorporated (NASDAQ: GPRO ... 2011, with total revenues of $135.9 million and non-GAAP earnings ... record sales of APTIMA women,s health products in the second ... revenue to decline compared to strong sales a year ago," ...
... AllograftPossibilities.org has rapidly grown into ... and transplant on the web. Although it has the ... donation is still lesser understood by the general public. ... and distributor of bone and soft-tissue allografts for use ...
Cached Biology Technology:How bats stay on target despite the clutter 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 2AllograftPossibilities.org Meets Unmet Need for Consumer-Oriented Information on Tissue Donation, Transplantation on the Internet 3
(Date:1/22/2015)... NEW YORK and POINT ROBERTS, Washington ... global news source covering leading sectors including technology and tech ... Personal Privacy marketplace featuring master pickpocket and security consultant ... wallet is stolen and talks about the Wocket™ biometric smart ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... levels of copper and iron to Alzheimer,s disease, heart disease, ... Chemical Research in Toxicology suggests specific steps that older ... of these metals in their bodies. "This story of copper ... of public health significance, is virtually unknown to the general ...
... research that blueberries one of the richest sources ... memory. They said the study establishes a basis for ... deserve their growing reputation as a memory enhancer. A ... of Agricultural and Food Chemistry , a bi-weekly publication. ...
... N.C. Duke University has received a $3.7 million contract ... develop a rapid and accurate genomic-based diagnostic test that can ... a dirty bomb or nuclear attack. In the event that ... could receive up to $43.6 million from the contract. ...
Cached Biology News:Duke awarded up to $43 million to develop test for dirty bomb/radiation exposure 2Duke awarded up to $43 million to develop test for dirty bomb/radiation exposure 3
... against a partial recombinant NFKBIB. ... a.a) partial recombinant protein with GST tag. ... Accession: BC015528 Protein ... 604495, GeneID: 4793 ...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... BD PhosFlow Perm/Wash Buffer I can be ... signaling proteins to permeabilize cells and to ... wash buffer. Because saponin-mediated cell permeabilization is ... keep the cells in the presence of ...
Mouse polyclonal antibody raised against a partial recombinant PREB. NCBI Entrez Gene ID = 10113...
Biology Products: